The Monkeypox Vaccine And Treatment Market Size is valued at 85.86 Million in 2023 and is predicted to reach 212.34 Million by the year 2031 at an 12.39 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
Humans can contract monkeypox by coming into intimate contact with an animal or person with the disease and by contact with contaminated objects. A viral zoonotic illness called monkeypox primarily affects tropical rainforest regions. It frequently manifests clinically as a rash, fever, and swollen lymph nodes and can cause various health issues. The monkeypox vaccines employed in the smallpox eradication operation also offered protection from that disease. One of the more recent vaccinations created is licensed to prevent monkeypox. The market is expected to be driven by elements like the rising incidence of monkeypox infection worldwide and the rising demand for treatment and prevention strategies. In addition, a surge in product approvals and rising government efforts to fund research into monkeypox infection are anticipated to propel market expansion. As of September 8, 2022, 56,609 cases had been reported worldwide, with 18 fatalities, according to CDC data. Most cases have been reported in the United States and Europe.
Market participants are encouraged by the rising incidence rates in these places to create cutting-edge drugs to lessen the disease burden there. Additionally, it is projected that several government programs for the supply, distribution, and availability of vaccinations to prevent infection will promote market growth in the years to come. The EUA and ongoing regulatory approvals both help the market grow. The market is anticipated to be driven by increased R&D and the smallpox vaccine as an off-label product for vaccination against monkeypox.
The Monkeypox Vaccine And Treatment market is segmented on the product, route of administration and end-use. Based on product, the market is segmented into Vaccines (JYNNEOS/ Imvanex, Smallpox Vaccine, Others), Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others) and Vaccinia Immune Globulin (VIG). Based on gender, Monkeypox Vaccine And Treatment market is segmented into males, females and Others. Based on the route of administration, the Monkeypox Vaccine And Treatment market is segmented into Oral and Injectable. Based on end-use, the Monkeypox Vaccine And Treatment market is segmented into Hospitals, Specialty Clinics and Others.
The market's leading segment was drugs. Some of the main drivers of the expansion include an expanding patient population for monkeypox disease, an increase in the use of antiviral drugs, and high treatment costs for the symptomatic management of the illness. However, the vaccine segment is anticipated to grow significantly. Increased use of vaccines against monkeypox infection, greater public awareness of vaccination, and intensive R&D efforts to create novel medicines are all predicted to boost category expansion. Additionally, several government measures to increase vaccine accessibility are projected to support category growth.
Hospitals grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. Growth is anticipated to be fueled by an increase in hospitalizations brought on by the monkeypox outbreak and a rise in the demand for therapeutic items used for symptomatic treatment in hospitals. Additionally, several initiatives launched by governmental organizations like the American Hospital Association and the Department of Health and Human Services to enhance the care and ongoing surveillance of patients with monkeypox infections are growing the hospital's patient base.
The North American Monkeypox Vaccine And Treatment market is expected to register the highest market share in revenue in the near future due to numerous key individuals and the numerous strategic efforts they have made. Additionally, it is anticipated that increased vaccination awareness and an increase in illness prevalence will encourage regional market growth. Furthermore, it is projected that solid government backing and increased R&D spending will create profitable growth prospects for the North American region. In addition, Asia Pacific is projected to grow rapidly in the global Monkeypox Vaccine And Treatment market. Monkeypox infections are arising, and research and development funds are being spent to establish preventative and therapeutic measures. As infection rates rise in countries around the Asia Pacific, including Australia, Singapore, and India, the market is expected to grow.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 85.86 Million |
|
Revenue Forecast In 2031 |
USD 212.34 Million |
|
Growth Rate CAGR |
CAGR of 12.39 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product, Gender, Route of Administration, End-Use |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Bavarian Noric; SIGA Technologies; Chimerix; EMERGENT; Gilead Sciences, Inc.Enthoven, Pulviver, Wulro Bv, and Venky’s(India) Limited |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Monkeypox Vaccine and Treatment Market Snapshot
Chapter 4. Global Monkeypox Vaccine and Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis
5.1. by Product Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product Type:
5.2.1. Vaccine
5.2.1.1. JYNNEOS/ Imvanex
5.2.1.2. Smallpox Vaccine
5.2.1.3. Others
5.2.2. Drugs
5.2.2.1. Tecovirimat
5.2.2.2. Brincidofovir
5.2.2.3. Cidofovir
5.2.2.4. Others
5.2.3. Vaccinia Immune Globulin (VIG)
Chapter 6. Market Segmentation 2: by Gender Estimates & Trend Analysis
6.1. by Gender & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Gender:
6.2.1. Male
6.2.2. Female
6.2.3. Others
Chapter 7. Market Segmentation 3: by Route of Administration Estimates & Trend Analysis
7.1. by Route of Administration & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Route of Administration:
7.2.1. Oral
7.2.2. Injectable
Chapter 8. Market Segmentation 4: by End-use Estimates & Trend Analysis
8.1. by End-use & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-use:
8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Others
Chapter 9. Monkeypox Vaccine and Treatment Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Monkeypox Vaccine and Treatment Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
9.1.2. North America Monkeypox Vaccine and Treatment Market Revenue (US$ Million) Estimates and Forecasts by Gender, 2024-2031
9.1.3. North America Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
9.1.4. North America Monkeypox Vaccine and Treatment Market revenue (US$ Million) by End-use, 2024-2031
9.1.5. North America Monkeypox Vaccine and Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.2. Europe
9.2.1. Europe Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Product Type, 2024-2031
9.2.2. Europe Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Gender, 2024-2031
9.2.3. Europe Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
9.2.4. Europe Monkeypox Vaccine and Treatment Market revenue (US$ Million) by End-use, 2024-2031
9.2.5. Europe Monkeypox Vaccine and Treatment Market revenue (US$ Million) by country, 2024-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Product Type, 2024-2031
9.3.2. Asia Pacific Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Gender, 2024-2031
9.3.3. Asia-Pacific Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
9.3.4. Asia-Pacific Monkeypox Vaccine and Treatment Market revenue (US$ Million) by End-use, 2024-2031
9.3.5. Asia Pacific Monkeypox Vaccine and Treatment Market revenue (US$ Million) by country, 2024-2031
9.4. Latin America
9.4.1. Latin America Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Product Type, 2024-2031
9.4.2. Latin America Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Gender, 2024-2031
9.4.3. Latin America Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
9.4.4. Latin America Monkeypox Vaccine and Treatment Market revenue (US$ Million) by End-use, 2024-2031
9.4.5. Latin America Monkeypox Vaccine and Treatment Market revenue (US$ Million) by country, 2024-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Product Type, 2024-2031
9.5.2. Middle East & Africa Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Gender, 2024-2031
9.5.3. Middle East & Africa Monkeypox Vaccine and Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
9.5.4. Middle East & Africa Monkeypox Vaccine and Treatment Market revenue (US$ Million) by End-use, 2024-2031
9.5.5. Middle East & Africa Monkeypox Vaccine and Treatment Market revenue (US$ Million) by country, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Bavarian Noric
10.2.2. SIGA Technologies
10.2.3. Chimerix
10.2.4. EMERGENT
10.2.5. Gilead Sciences, Inc
10.2.6. Other Prominent Players
By Product-
By Gender-
By Route of Administration-
By End-Use
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
